IN THE CLAIMS

Please cancel claims 8, 17 and 18, and add new claims 30, 31, 32, 33 and 34 as follows:

CLAIM 30 A recombinant immunotoxin polypeptide and the pharmaceutically acceptable salts thereof, wherein the polypeptide comprises the polypeptide coded for by the nucleotide sequence shown in Figure 15 (SEQ. ID. No. 2).

CLAIM 31 A recombinant immunotoxin polypeptide and the pharmaceutically acceptable salts thereof, wherein the polypeptide comprises the polypeptide encoded by the one or more nucleotide sequences which hybridize to the nucleotide sequence of claim 30 (SEQ. ID. No. 2) under stringent hybridization conditions.

CLAIM 32 A recombinant immunotoxin polypeptide and the pharmaceutically acceptable salts thereof, wherein the polypeptide comprises the polypeptide encoded by any nucleotide sequence which hybridizes to the said one or more nucleotide sequences of claim 31 under stringent hybridization conditions.

CLAIM 33 A recombinant immunotoxin polypeptide and pharmaceutically acceptable salts thereof according to claim 2, wherein the CD3-binding domain comprises the Fv region, or a CD3-binding fragment thereof of an antibody selected from: monoclonal antibody UCHT-1, an antibody having a variable region which is at least 99% identical to the variable region of UCHT-1 and is at least 95% as effective on a molar basis in competing with UCHT-1 for binding to human CD3 antigen and having at least one sequence segment of at least five amino acids of human origin.

CLAIM 34 A recombinant immunotoxin polypeptide selected from polypeptides having residues 1-601, 2-601 or 3-601 of SEQ. ID. No. 1 and their pharmaceutically acceptable salts thereof.